The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy.

We sought to develop and validate a standardized cutaneous nerve regeneration model and to define the rate of epidermal nerve fibre (ENF) regeneration first in healthy control subjects and then in neuropathic and neuropathy-free subjects with diabetes. Next, we assessed the effect of different factors on the rate of nerve fibre regeneration and investigated whether such an approach might offer insight into novel trial designs and outcome measures. All subjects had a standardized topical capsaicin dressing applied to the distal lateral thigh. ENF densities derived from skin biopsies were determined at baseline, after capsaicin treatment and at reinnervation time points. For each subject, the best fit line from post-denervation data was determined and the slope was used as the rate of regeneration. In healthy control subjects, regeneration was correlated with psychophysical sensory testing, electron microscopy studies and immunohistochemistry with alternative axonal membrane markers. Topical capsaicin application produced complete or nearly complete denervation of the epidermis in both control subjects and people with diabetes. The rate of regeneration was associated with the baseline ENF density (P < 0.001), but not age (P = 0.75), gender (P = 0.18), epidermal thickness (P = 0.4) or post-capsaicin treatment density (P = 0.7). ENF regeneration, as determined by recovery of ENF density, occurred at a rate of 0.177 +/- 0.075 fibres/mm/day in healthy control subjects and was significantly reduced in subjects with diabetes (0.074 +/- 0.064, P < 0.001) after adjusting for changes in baseline ENF density. Among subjects with diabetes, the presence of neuropathy was associated with a further reduction in regenerative rate (0.10 +/- 0.07 versus 0.04 +/- 0.03, P = 0.03), though diabetes type (P = 0.7), duration of diabetes (P = 0.3) or baseline glycated haemoglobin (P = 0.6) were not significant. These results have several implications. First, topical capsaicin application can produce a uniform epidermal nerve fibre injury that is safe and well tolerated, and offers an efficient strategy to measure and study nerve regeneration in man. Secondly, using our techniques, reduced rates of nerve regeneration were found in people with diabetes without evidence of neuropathy and indicate that abnormalities in peripheral nerve function are present early in diabetes, before signs or symptoms develop. These results suggest that regenerative neuropathy trials could include non-neuropathic subjects and that trial duration can be dramatically shortened.

[1]  D. Zochodne,et al.  A prospective quantitative study of sensory deficits after whole sural nerve biopsies in diabetic and nondiabetic patients Surgical approach and the role of collateral sprouting , 1998, Neurology.

[2]  Y. Kocabey,et al.  Outcomes of carpal tunnel release in diabetic and non‐diabetic patients , 2002, Acta neurologica Scandinavica.

[3]  S. Britland,et al.  Association of Painful and Painless Diabetic Polyneuropathy With Different Patterns of Nerve Fiber Degeneration and Regeneration , 1990, Diabetes.

[4]  D. Zochodne,et al.  The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. , 2000, Brain : a journal of neurology.

[5]  M. Nolano,et al.  Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation , 1999, Pain.

[6]  S. Tripp,et al.  Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy , 2001, Neurology.

[7]  M. Bisby Axonal transport of labeled protein and regeneration rate in nerves of streptozocin-diabetic rats , 1980, Experimental Neurology.

[8]  J. McArthur,et al.  Cutaneous innervation in sensory neuropathies , 1995, Neurology.

[9]  P. Fernyhough,et al.  Role of Neurotrophins in Diabetic Neuropathy and Treatment with Nerve Growth Factors , 1997, Diabetes.

[10]  Justin C McArthur,et al.  Epidermal reinnervation after intracutaneous axotomy in man , 2003, The Journal of comparative neurology.

[11]  P. Watkins,et al.  DIABETIC NEUROPATHY: ABNORMALITIES OF SCHWANN CELL AND PERINEURIAL BASAL LAMINAE. IMPLICATIONS FOR DIABETIC VASCULOPATHY , 1989, Neuropathology and applied neurobiology.

[12]  M. Pfeifer,et al.  Clinical Trials of Diabetic Neuropathy: Past, Present, and Future , 1995, Diabetes.

[13]  C. Pierson,et al.  Early Gene Responses of Trophic Factors in Nerve Regeneration Differ in Experimental Type 1 and Type 2 Diabetic Polyneuropathies , 2002, Journal of neuropathology and experimental neurology.

[14]  C. Pierson,et al.  Insulin Deficiency Rather than Hyperglycemia Accounts for Impaired Neurotrophic Responses and Nerve Fiber Regeneration in Type 1 Diabetic Neuropathy , 2003, Journal of neuropathology and experimental neurology.

[15]  C. Sumner,et al.  The spectrum of neuropathy in diabetes and impaired glucose tolerance , 2003, Neurology.

[16]  R. Hughes Treating Nerves: From Anecdote to Systematic Review , 2003, Journal of the Royal Society of Medicine.

[17]  A. Asbury,et al.  Painful diabetic neuropathy. A morphometric study. , 1976, Archives of neurology.

[18]  W. Dixon,et al.  Efficient analysis of experimental observations. , 1980, Annual review of pharmacology and toxicology.

[19]  G. Wendelschafer‐Crabb,et al.  Quantitation of epidermal nerves in diabetic neuropathy , 1996, Neurology.

[20]  T. Vilén,et al.  Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. , 1988, The New England journal of medicine.

[21]  R. Myers,et al.  Delayed nerve regeneration in streptozotocin diabetic rats , 1986, Muscle & nerve.

[22]  G. Wendelschafer‐Crabb,et al.  Utility of Skin Biopsy in Diabetic Neuropathy , 1996, Seminars in neurology.

[23]  E. Feldman,et al.  Clinical Testing in Diabetic Peripheral Neuropathy , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[24]  W. Schneider Degeneration and Regeneration , 2020, Definitions.

[25]  M. Pfeifer,et al.  Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs? , 1997, Diabetes.

[26]  M B Brown,et al.  A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy , 1994, Diabetes Care.

[27]  A. Boulton,et al.  Myelinated nerve fibre regeneration in diabetic sensory polyneuropathy: correlation with type of diabetes , 2004, Acta Neuropathologica.

[28]  M. Nolano,et al.  Intradermal Injection of Capsaicin in Humans Produces Degeneration and Subsequent Reinnervation of Epidermal Nerve Fibers: Correlation with Sensory Function , 1998, The Journal of Neuroscience.

[29]  F. Buchthal,et al.  Sensory action potentials and biopsy of the sural nerve in neuropathy. , 1978, Brain : a journal of neurology.

[30]  J. McArthur,et al.  Epidermal nerve fiber density: normative reference range and diagnostic efficiency. , 1998, Archives of neurology.

[31]  Matthew D. Davis,et al.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. , 2002, JAMA.

[32]  Joseph F. Williams Annual Review of Pharmacology , 1975 .